RIGL
Rigel Pharmaceuticals IncCompany with tickers: RIGL
Market Cap
$684.39M
Shares Outstanding
18,502,080
CIK
1034842
CUSIP
766559702
13F Activity (30d)
4 filings
3 filers
Website
Visit website
Investor Relations
Investor relations
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $58,818,000 | USD | 2026-03-31 | 10-Q | 2026-05-05 |
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | — | ||||
| Research & Development | $11,676,000 | USD | 2026-03-31 | 10-Q | 2026-05-05 |
| Operating Income | $11,885,000 | USD | 2026-03-31 | 10-Q | 2026-05-05 |
| Net Income | $8,654,000 | USD | 2026-03-31 | 10-Q | 2026-05-05 |
| EPS (Basic) | $0.47 | USD/shares | 2026-03-31 | 10-Q | 2026-05-05 |
| EPS (Diluted) | $0.44 | USD/shares | 2026-03-31 | 10-Q | 2026-05-05 |
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
By Segment (USD)
| Component | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Single Reportable Segment | $120,242,000 | $116,882,000 | $179,278,000 | $294,282,000 |
By Product & Service (USD)
| Component | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|---|---|---|---|
| Gross Product | $16,953,000 | $53,082,000 | $76,470,000 | $81,186,000 | $108,523,000 | $147,058,000 | $209,924,000 | $309,961,000 |
| Product | $13,947,000 | $43,772,000 | $61,696,000 | $63,010,000 | $76,718,000 | $104,294,000 | $144,902,000 | $231,983,000 |
| Contract Revenues From Collaborations | $30,562,000 | $15,516,000 | $46,925,000 | $75,726,000 | $39,024,000 | $11,488,000 | $34,376,000 | $62,034,000 |
| Release Of Share Cost Liability | — | — | — | — | — | $0 | $0 | $39,981,000 |
| Royalty Delivery Of Drug Supplies And Others | — | — | — | $3,298,000 | $6,092,000 | $11,413,000 | $20,376,000 | $19,053,000 |
| Development Milestones | — | $5,500,000 | $2,100,000 | $1,875,000 | $25,000,000 | $75,000 | $0 | $3,000,000 |
| Government Contract | — | — | — | $10,500,000 | $4,500,000 | $1,100,000 | $0 | $265,000 |
| License | $30,562,000 | $8,696,000 | $40,358,000 | $70,553,000 | $7,932,000 | $0 | $14,000,000 | $0 |
| Discounts And Allowances | $-3,006,000 | $-9,310,000 | $-14,774,000 | $-18,176,000 | $-31,805,000 | $-42,764,000 | $-65,022,000 | $-77,978,000 |
| Research And Development Services And Others | — | $1,320,000 | $4,467,000 | $3,298,000 | $6,092,000 | — | — | — |
| Rezlidhia | — | — | — | — | $900,000 | — | — | — |